iqvia glp-1 prescriptions q3 2024 semaglutide tirzepatide weight loss drug iqvia prescriptions semaglutide tirzepatide q3 2024 Shortages improve for Lilly's GLP-1 weight loss drugs, bumping sales forecast by $3bn-bsmoothhr India's obesity and diabetes market

draft guidance for industry, January 2025: ika O, Haluzk M, Jude EB

There is no evidence of a physical withdrawal syndrome associated with tirzepatide discontinuation, meaning patients do not experience acute symptoms similar to those seen with certain other medications

Similar to Ozempic and Wegovy, Victoza and Saxenda share the same active ingredient liraglutide but are FDA-approved for different indications

Omaha Semaglutide (and medications like it) can lead to approximately a 15% decrease in body weight

This type of loss follows specific patterns: receding hairline and crown thinning in men, widening part and diffuse thinning in women